GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » Beneish M-Score

Amoy Diagnostics Co (SZSE:300685) Beneish M-Score : -2.71 (As of May. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.71 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Amoy Diagnostics Co's Beneish M-Score or its related term are showing as below:

SZSE:300685' s Beneish M-Score Range Over the Past 10 Years
Min: -3.39   Med: -2.1   Max: -0.72
Current: -2.71

During the past 12 years, the highest Beneish M-Score of Amoy Diagnostics Co was -0.72. The lowest was -3.39. And the median was -2.10.


Amoy Diagnostics Co Beneish M-Score Historical Data

The historical data trend for Amoy Diagnostics Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amoy Diagnostics Co Beneish M-Score Chart

Amoy Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.79 -2.31 -1.90 -1.93 -2.67

Amoy Diagnostics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.11 -2.14 -2.64 -2.67 -2.71

Competitive Comparison of Amoy Diagnostics Co's Beneish M-Score

For the Diagnostics & Research subindustry, Amoy Diagnostics Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amoy Diagnostics Co's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Amoy Diagnostics Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Amoy Diagnostics Co's Beneish M-Score falls into.



Amoy Diagnostics Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Amoy Diagnostics Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8824+0.528 * 0.9823+0.404 * 0.6095+0.892 * 1.3011+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8805+4.679 * -0.021966-0.327 * 1.4446
=-2.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥522 Mil.
Revenue was 233.289 + 335.915 + 248.885 + 263.542 = ¥1,082 Mil.
Gross Profit was 197.031 + 284.652 + 208.008 + 219.87 = ¥910 Mil.
Total Current Assets was ¥1,668 Mil.
Total Assets was ¥1,974 Mil.
Property, Plant and Equipment(Net PPE) was ¥191 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥388 Mil.
Total Current Liabilities was ¥147 Mil.
Long-Term Debt & Capital Lease Obligation was ¥46 Mil.
Net Income was 64.199 + 87.751 + 46.972 + 69.444 = ¥268 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 80.578 + 83.466 + 72.271 + 75.42 = ¥312 Mil.
Total Receivables was ¥454 Mil.
Revenue was 195.164 + 242.921 + 206.751 + 186.458 = ¥831 Mil.
Gross Profit was 163.683 + 195.538 + 172.494 + 154.976 = ¥687 Mil.
Total Current Assets was ¥1,306 Mil.
Total Assets was ¥1,671 Mil.
Property, Plant and Equipment(Net PPE) was ¥205 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥339 Mil.
Total Current Liabilities was ¥65 Mil.
Long-Term Debt & Capital Lease Obligation was ¥48 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(521.711 / 1081.631) / (454.416 / 831.294)
=0.482337 / 0.546637
=0.8824

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(686.691 / 831.294) / (909.561 / 1081.631)
=0.826051 / 0.840916
=0.9823

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1667.794 + 190.95) / 1974.358) / (1 - (1306.2 + 204.636) / 1671.422)
=0.058558 / 0.096077
=0.6095

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1081.631 / 831.294
=1.3011

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 204.636)) / (0 / (0 + 190.95))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(388.135 / 1081.631) / (338.807 / 831.294)
=0.358842 / 0.407566
=0.8805

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((45.738 + 147.358) / 1974.358) / ((48.374 + 64.783) / 1671.422)
=0.097802 / 0.067701
=1.4446

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(268.366 - 0 - 311.735) / 1974.358
=-0.021966

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Amoy Diagnostics Co has a M-score of -2.71 suggests that the company is unlikely to be a manipulator.


Amoy Diagnostics Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Amoy Diagnostics Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Amoy Diagnostics Co (SZSE:300685) Business Description

Traded in Other Exchanges
N/A
Address
39 Dingshan Road, Haicang District, Xiamen, CHN, 361027
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Executives
Ruan Li Directors, executives
Zheng Hui Bin Directors, executives
Chen Ying Directors, executives
Luo Jie Min Executives
Zhu Guan Shan Directors, executives
Yang Shou Qian Securities Affairs Representative
Zhou Wen Gang Executives
Zhou Xue Lin Independent director
Hu Xu Bo Director

Amoy Diagnostics Co (SZSE:300685) Headlines

No Headlines